🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million new cases each year. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Secure Authorization

One new antibiotic, also known as Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization marks a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per results released by a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The research enrolled nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to license and sell the drug in many regions with limited resources.

Doctors on the front lines have expressed positive views. The availability of a one-pill regimen like this is hailed as a "critical tool" for managing the epidemic. This is deemed essential to reduce the burden of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.